1. Home /
    2. Altai Protocol Library /
  2. New Drug: Tepotinib for NSCLC with MET Exon14 skipping mutations

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Kütüphanede Ara Ara
Altai Protocol Library

New Drug: Tepotinib for NSCLC with MET Exon14 skipping mutations

New Drug: Tepotinib for NSCLC with MET Exon14 skipping mutations
Study:
  • Open-label phase II trial (VISION)
  • Locally advanced or metastatic NSCLC with MET exon 14 skipping mutations (N=99)
Efficacy:
  • ORR: 46% [36%-57%]
  • Median DoR: 11.1 mos [7.2 mos – NE]
  • Median PFS: 8.5 mos [5.1 – 11.0 mos]
Safety:
  • Grade 3-4 AEs: Edema (7%), pleural effusion (3%), increased amylase/lipase (3%)

N Engl J Med. Published online May 29, 2020

Paik PK, et al. Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

https://doi.org/10.1056/NEJMoa2004407

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More